Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 3/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.38 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | CTSH | P09668 | 1/20 | 0.37 |
| ▸ | GRN | P28799 | 1/20 | 0.37 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13543015 | 0.98 | LTA4H (0.38) | LTA4HCTSKCTSSCPB2SLC1A3 | |
| SCHEMBL13543011 | 0.94 | SLC1A3 (0.36) | LTA4HCTSKCTSSCPB2SLC1A3 | |
| SCHEMBL13543023 | 0.90 | CTSS (0.36) | CTSKCTSSCPB2SLC1A3SLC1A2 | |
| Hydrochloric Acid SCHEMBL7838392 | 0.84 | CPB2 (0.38) | LTA4HCTSKCTSSCPB2SLC1A3 | |
| SCHEMBL13423681 | 0.83 | METAP1 (0.43) | LTA4HSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL2375470 | 0.82 | CTSK (0.36) | LTA4HCTSKCTSSCPB2CTSL | |
| SCHEMBL5273660 | 0.81 | CTSK (0.39) | LTA4HCTSKCTSSCPB2SLC1A3 | |
| SCHEMBL6053853 | 0.80 | CTSK (0.38) | LTA4HCTSKCTSSCPB2SLC1A3 | |
| SCHEMBL1246701 | 0.79 | LTA4H (0.37) | LTA4HCTSKCTSSSLC1A3SLC1A2 | |
| SCHEMBL5936761 | 0.79 | LTA4H (0.37) | LTA4HCTSKCTSSSLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796256-B2 | Substituted thiazolidinedione indazoles, indoles and benzotriazoles as estrogen-related receptor-α modulators | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-05 | — | — | US | disclosed |
| US-20110294780-A1 | SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-a MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-01 | — | — | US | disclosed |
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20070004701-A1 | Topoisomerase inhibitors | PROPHARMACON, INC. (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004701-A1 | Topoisomerase inhibitors | TOP1, TOP2A, TOP2B | LTA4H 4039/4885CTSK 2346/4885CTSS 2864/4885 |
| US-20110294780-A1 | SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-a MODULATORS | ESR2, IGF1R, ESRRA | LTA4H 4063/4885CTSK 2234/4885CTSS 1975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.